MEDIA RELEASE
FOR IMMEDIATE RELEASE

15 JANUARY 2026

A*STAR LICENSES TECHNOLOGY TO CALLIO THERAPEUTICS

SINGAPORE — The Agency for Science, Technology and Research (A*STAR) and Callio Therapeutics along with its subsidiary Callio Operating Co., Inc. (Callio Therapeutics) have signed a licence agreement for the use of A*STAR's multicistronic expression vector technology to enable high-yield production of Callio Therapeutics' antibody-drug candidates.

Under the agreement, Callio Therapeutics gains non-exclusive, worldwide commercial rights for the application of A*STAR's technology for the development and manufacturing of Callio Therapeutics' recombinant antibody drugs.

Advanced Cell Line Development Technology

The cell line development technology, developed at A*STAR Bioprocessing Technology Institute (A*STAR BTI), centres on a multicistronic expression vector that enables the generation of high-producing chinese hamster ovary (CHO) cell lines for recombinant proteins and antibodies.

The platform's integrated design combines optimal vector architecture, strong promoters, and finely tuned selection elements to drive superior antibody yields. The multicistronic configuration allows a single DNA construct to encode all necessary antibody components whilst maintaining proper ratios and enabling stringent selection of top-performing production clones. The technology enables antibody titres of approximately 5 grams per litre in typical fed-batch cultures and allows high-producing cell lines to be established in as little as 12 weeks.

Professor Koh Boon Tong, Executive Director of A*STAR BTI, shared: " Our multicistronic expression platform offers biopharmaceutical partners a robust solution for manufacturing complex antibody therapeutics at scale. This partnership reflects the platform's relevance for emerging therapeutic modalities, and we look forward to supporting the advancement of innovative cancer treatments."

– END –

About A*STAR Bioprocessing Technology Institute (A*STAR BTI)

Established in 1990, A*STAR BTI is positioned as Singapore's pillar of research and development for the biomanufacturing sector. The institute's core capabilities span across the bioprocessing value chain, largely comprising Product Innovation, Cell Line Development, Media Development, Downstream Processing, Process Development and Scale-up, and Analytical Science & Technologies. Through strategic partnerships and application-driven research, A*STAR BTI seeks to create value and impact in product markets including biologics, cell and gene therapy, exosomes, vaccines, engineered tissues, process analytical technologies and cell culture systems. For more information on BTI, visit **www.a-star.edu.sg/bti**.

About the Agency for Science, Technology and Research (A*STAR)

The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.

Follow us on
Facebook | LinkedIn | Instagram | YouTube | TikTok